Divi's Laboratories Limited (BOM:532488)

Market Cap	1.64T +10.6%
Revenue (ttm)	103.14B +13.6%
Net Income	24.79B +19.9%
EPS	93.37 +19.9%
Shares Out	n/a
PE Ratio	66.06
Forward PE	55.16
Dividend	30.00 (0.50%)
Ex-Dividend Date	Jul 25, 2025

Volume	13,194
Average Volume	16,398
Open	6,101.10
Previous Close	6,188.20
Day's Range	6,062.20 - 6,199.05
52-Week Range	4,941.70 - 7,077.70
Beta	n/a
RSI	48.81
Earnings Date	Feb 11, 2026

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its pro...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1990
• Employees: 10,542
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532488

Financial Performance

In fiscal year 2025, Divi's Laboratories's revenue was 93.60 billion, an increase of 19.31% compared to the previous year's 78.45 billion. Earnings were 21.91 billion, an increase of 36.94%.